TargetMol

Maxacalcitol-D6

Product Code:
 
TAR-T11952
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T11952-10mg10mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11952-50mg50mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11952-1mg1mg£1,156.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11952-5mg5mg£3,686.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Maxacalcitol-D6 is a non-calcemic vitamin D3 analog and VDR ligand of VDR-like receptors.Maxacalcitol-D6 is the deuterated form of Maxacalcitol (22-Oxacalcitriol).
CAS:
T11952
Formula:
C26H36D6O4
Molecular Weight:
424.65
Purity:
0.98
SMILES:
O[C@@H](C[C@H](O)C/1=C)CC1=CC=C2[C@@](CC[C@@H]3[C@@H](OCCC(C([2H])([2H])[2H])(C([2H])([2H])[2H])O)C)([H])[C@]3(C)CCC2

References

1. Monier-Faugere et al 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int. (1999)55 821. 2. Barroga et al Inhibitory effects of 22-oxa-calcitriol and all-trans retinoic acid on the growth of a canine osteosarcoma derived cell-line in vivo and its pulmonary metastasis in vivo. Res.Vet.Sci. (2000)68 79. 3. Inoue K, Matsui I, Hamano T, Fujii N, Shimomura A, Nakano C, Kusunoki Y, Takabatake Y, Hirata M, Nishiyama A, Tsubakihara Y, Isaka Y, Rakugi H.Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pS 4. Karashima T, Hashikawa K, Ono F, Eguchi H, Hamada T, Ishii N, Dainichi T, Yasumoto S, Tsuruta D, Hashimoto T.Successful Treatment of Bowen's Disease with Topical Maxacalcitol.Acta Derm Venereol. 2012 Jan 26.